Trial reportAlimentary pharmacology & therapeutics2025
Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial.
Trial report in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04133194 (Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis (EASI-trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background5-Aminosalicylate (5-ASA) is recommended for the treatment of mild-to-moderate ulcerative colitis (UC). However, adherence may be low; poor adherence is associated with an increased risk for flares.
aimTo investigate whether a regimen of a single 1600 mg tablet of 5-ASA improves adherence with preserved remission rates compared to a conventional regimen of three 800 mg tablets.
methodsWe enrolled 178 patients with UC (89 per group) in this open-label randomised controlled phase IV trial. Patients had to have stable remission on 5-ASA for at least 2 months and no concomitant diseases that could affect compliance. We randomised patients (1:1) to either receive Asacol 1600 mg single tablet or Asacol 2400 mg (three tablets of 800 mg once daily) for 12 months. Patients were assessed five times during the 12 months, where medicine was delivered and received, blood and stool samples were collected and symptom scores were determined.
resultsEighty-two patients taking a single tablet and 78 taking three tablets were adherent (p = 0.32). Fewer patients in the 1600 mg group missed doses (24.5 vs. 26.5). There was no difference in the number of relapses or proportions experiencing relapse. Neither adherence nor treatment group was a significant predictor of relapse.
conclusionThe single-tablet lower dose treatment could be a feasible alternative to the conventional three-tablet regimen.
trial registrationThe study was registered at Clinicaltrials.gov (ID NCT04133194) and approved by The Danish Medicine Agency and The National Committee on Health Research Ethics (EudraCT 2019-002070-31).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.